
The U.S. Food and Drug Administration has granted Fast Track designation to Pfizer’s (NYSE:PFE) Ervogastat/Clesacostat Combination therapy for the treatment of Non-Alcoholic Steatohepatitis (NASH).
The Ervogastat/Clesacostat combination is being investigated in an ongoing Phase 2 clinical trial evaluating the impact of treatment on resolution of NASH or improvement in liver fibrosis.